CLINICAL TRIALS PROFILE FOR KIMYRSA
✉ Email this page to a colleague
505(b)(2) Clinical Trials for KIMYRSA
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Formulation | NCT03873987 ↗ | Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients | Completed | Melinta Therapeutics, Inc. | Phase 1 | 2019-07-16 | This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa versus the approved oritavancin formulation in subjects with acute bacterial skin and skin structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of oritavancin |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for KIMYRSA
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03873987 ↗ | Relative Exposure and Safety Study of Kimyrsa in ABSSSI Patients | Completed | Melinta Therapeutics, Inc. | Phase 1 | 2019-07-16 | This study is being conducted to evaluate the pharmacokinetic (PK) and safety of Kimyrsa versus the approved oritavancin formulation in subjects with acute bacterial skin and skin structure infection (ABSSSI). Kimyrsa adjusts the infusion time, concentration and reconstitution/administration solutions of a single 1200 mg intravenous (IV) infusion of oritavancin |
| NCT05599295 ↗ | Study to Evaluate the Safety and Tolerability of Single-Dose Intravenous (IV) Oritavancin | Not yet recruiting | Melinta Therapeutics, Inc. | Phase 2 | 2022-10-31 | This protocol describes a randomized, open-label study to evaluate the safety and tolerability of single-dose intravenous (IV) oritavancin diphosphate (oritavancin) versus standard of care (SoC) antibiotics for the treatment of pediatric subjects with acute bacterial skin and skin structure infections (ABSSSIs). This study involves two oritavancin products, ORBACTIV® and KIMYRSATM. Oritavancin is the active drug substance in both ORBACTIV and KIMYRSA. This study protocol distinguishes the differences between ORBACTIV and KIMYRSA by providing product-specific data, and information and guidance for Investigators. "Oritavancin" is used to describe drug product data, and information and guidance that is not specific to ORBACTIV or KIMYRSA (i.e., applies to both). The study involves pharmacokinetic (PK) sampling and will evaluate clinical outcome assessments. The study was designed to capture adequate data while minimizing the impact to subjects and their caregivers. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for KIMYRSA
Condition Name
Clinical Trial Locations for KIMYRSA
Trials by Country
Clinical Trial Progress for KIMYRSA
Clinical Trial Phase
Clinical Trial Sponsors for KIMYRSA
Sponsor Name
